Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape

Snapshot: 2026-09-04

Shaanxi Multiple Myeloma Active Trials & Centers

As of 2026-09-04, there are 27 active clinical trials for multiple myeloma hosted across 15 tertiary medical centers in Shaanxi (including The Second Affiliated Hospital of Xi'an Jiaotong University, The First Affiliated Hospital of Xi'an Jiaotong University, The Second Affiliated Hospital of Xi'an Jiaotong University, etc.).

Active Trials

Hospitals

Therapies

CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (15)

The Second Affiliated Hospital of Xi'an Jiaotong UniversityThe First Affiliated Hospital of Xi'an Jiaotong UniversityThe Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an Central HospitalBaoji Central HospitalXianyang Central HospitalXijing Hospital affiliated to Air Force Medical University西安国际医学中心有限公司西安交通大学医学院附属第二医院The Second Affiliated Hospital of Xi'an Jiaotong UniversityFirst Affiliated Hospital of Air Force Medical University (Xijing Hospital)The Second Affiliated Hospital of Air Force Medical University of the Chinese People's Liberation ArmyThe First Affiliated Hospital of PLA Air Force Medical UniversityShaanxi Provincial People's HospitalThe First Affiliated Hospital of Air Force Medical University (Xijing Hospital)

Active Studies in Shaanxi (27)

Population synthesized by CMDN

Showing 0 published English records of 27 registry trials.

All 27 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.

Back to National Landscape Filter Local Trials in the Trial Hub